m\(^6\)A-mRNA methylation regulates cardiac gene expression and cellular growth

Vivien Kmietczyk\(^{1,2,*}\), Eva Riechert\(^{1,2,*}\), Laura Kalinski\(^{1,2}\), Etienne Boileau\(^{1,2,3}\), Ellen Malovrh\(^{1,2}\), Brandon Malone\(^{1,2,3}\), Agnieszka Gorska\(^{1,2}\), Christoph Hofmann\(^{1,2}\), Eshita Varma\(^{1,2}\), Lonny Jürgensen\(^{1,2}\), Verena Kamuf-Schenk\(^{1,2}\), Janine Altmüller\(^{4,5}\), Rewati Tappu\(^{1,2}\), Martin Busch\(^{1,2}\), Patrick Most\(^{1,2}\), Hugo A Katus\(^{1,2}\), Christoph Dieterich\(^{1,2,3}\), Ellen Malovrh\(^{1,2}\), Eshita Varma\(^{1,2}\), Lonny Jürgensen\(^{1,2}\), Verena Kamuf-Schenk\(^{1,2}\), Janine Altmüller\(^{4,5}\), Rewati Tappu\(^{1,2}\), Martin Busch\(^{1,2}\), Patrick Most\(^{1,2}\), Hugo A Katus\(^{1,2}\), Christoph Dieterich\(^{1,2,3}\), Mirko Völkers\(^{1,2}\)

Conceptually similar to modifications of DNA, mRNAs undergo chemical modifications, which can affect their activity, localization, and stability. The most prevalent internal modification in mRNA is the methylation of adenosine at the N\(^6\)-position (m\(^6\)A). This returns mRNA to a role as a central hub of information within the cell, serving as an information carrier, modifer, and attenuator for many biological processes. Still, the precise role of internal mRNA modifications such as m\(^6\)A in human and murine-dilated cardiac tissue remains unknown. Transcriptome-wide mapping of m\(^6\)A in mRNA allowed us to catalog m\(^6\)A targets in human and murine hearts. Increased m\(^6\)A methylation was found in human cardio-myopathy. Knockdown and overexpression of the m\(^6\)A writer enzyme Mettl3 affected cell size and cellular remodeling both in vitro and in vivo. Our data suggest that mRNA methylation is highly dynamic in cardiomyocytes undergoing stress and that changes in the mRNA methylome regulate translational efficiency by affecting transcript stability. Once elucidated, manipulations of methylation of specific m\(^6\)A sites could be a powerful approach to prevent worsening of cardiac function.

DOI 10.26508/lsa.201800233 | Received 7 November 2018 | Revised 22 March 2019 | Accepted 22 March 2019 | Published online 9 April 2019

Introduction

Heart disease, especially heart failure (HF), is a frequent disorder with a considerable burden for our health-care system (Mudd & Kass, 2008; Bui et al, 2011). Although the development of HF depends on variable environmental influences, aberrant changes in myocardial gene expression represent a fundamental feature of both diseased human hearts and many animal models of HF (Tan et al, 2002). Numerous gene expression studies based on profiling of mRNA abundance in failing human heart tissues or experimental HF models have been performed providing large datasets describing the networks of gene expression control in diseased hearts (Koibataishi & Kass, 2012; Papait et al, 2013; Han et al, 2014). In contrast, only recent research has unveiled the importance of reversible mRNA modifications on gene expression control in different cellular systems (Meyer & Jaffrey, 2014), and previous studies did not capture gene expression control at the level of mRNA methylation in diseased cardiac myocytes. Reversible mRNA modifications have been proposed in 2010 by the He laboratory (He, 2010) and the discovery of fat mass and obesity-associated (Fto) and AlkB homolog 5 RNA demethylase (Alkbh5) proteins as m\(^6\)A demethylases in 2011 has finally shown the dynamic, reversible, and adjustable nature of m\(^6\)A RNA modifications (Jia et al, 2011). In mammals, the writer of m\(^6\)A is a multi-component enzyme consisting of methyltransferase-like 3 (Mettl3), methyltransferase-like 14 (Mettl14), and Wilms tumor 1-associated protein (Wtap) (Liu et al, 2014). In 2012, two groups independently developed methods to assess the in vivo methylation state of m\(^6\)A sites (Dominissini et al, 2012; Meyer et al, 2012), which allowed genome-wide mapping of m\(^6\)A modifications and unveiled the importance of reversible mRNA modifications on gene expression control (Geula et al, 2015; Wang et al, 2015). This work has shown that m\(^6\)A modifications of mRNAs occur and play a crucial role in gene expression control of development, cell growth, metabolism, cellular survival, and intracellular signaling (Fu et al, 2014). The presence of m\(^6\)A across different species; the conservation of writers, erasers, and readers; and the phenotypes associated with changes of m\(^6\)A suggest a fundamental role in physiology and pathophysiology.

Although previous studies did not investigate the role of mRNA modifications in pathological cardiac growth, published reports suggest that m\(^6\)A status regulates cell growth. First and importantly, m\(^6\)A RNA methylation regulates gene expression posttranscriptionally in...
Results and Discussion

Cardiac m<sup>6</sup>A mRNA methylome is dynamic and differs between healthy and diseased human cardiac tissue

Sequecing of m<sup>6</sup>A-specific immunoprecipitated mRNA allows genome-wide mapping of m<sup>6</sup>A modifications. m<sup>6</sup>A dot blots were performed on the m<sup>6</sup>A-positive (IP) and m<sup>6</sup>A-negative (Flow through) fractions and showed successful and specific pull-down of m<sup>6</sup>A-methylated RNA (Fig S1A). To further demonstrate that our protocol selectively enriches for m<sup>6</sup>A-methylated targets, we performed qRT-PCR on the fractions after RNA precipitation. A substantial enrichment of previously published m<sup>6</sup>A-methylated transcripts such as Dsc1 (Mathiyalagan et al, 2018) was detected in the IP fraction (Meyer et al, 2012). In contrast, transcripts that lack m<sup>6</sup>A enrichment, such as Ndel1, were undetectable in the IP fraction (Fig S1B).

Measurements of m<sup>6</sup>A level and sequencing of m<sup>6</sup>A-specific immunoprecipitated mRNA were performed in human failing, dilated cardiomyopathy (DCM) samples and compared with healthy myocardium (control). In line with a recently published report (Mathiyalagan et al, 2018), we found increased m<sup>6</sup>A levels in mRNAs (Fig 1A) isolated from human failing myocardium. We analyzed expression of m<sup>6</sup>A writers and erasers in human heart biopsies from a published DCM patient cohort (n = 33) compared with healthy controls (n = 24) by RNA-seq (Meder et al, 2017). These data did not show any significant changes of Mettl3 or Fto on the transcript level assessed by RNA-seq (Fig 1B). A trend in increased protein levels and RNA levels of Mettl3 could be observed in a small cohort of DCM hearts compared with control samples (Fig S1C), suggesting that only in the subset of DCM patients, Mettl3 expression levels increased.

We identified thousands of genes significantly enriched in the IP fraction from failing myocardium, whereas fewer transcripts were identified in healthy myocardium (Table S1). 1,595 disease-specific methylated transcripts in human DCM samples and only 331 control-specific transcripts were found (Fig 1C). These findings were validated by qRT-PCR of precipitated mRNA for DCM- or control-specific methylated targets chosen by highest enrichment (Fig S1E).

Next, Gene Ontology (GO) term analysis was performed for DCM-specific methylated transcripts. m<sup>6</sup>A-containing transcripts of DCM samples were significantly enriched for genes involved in gene transcription, cell adhesion, and heart development (Fig 1D and E). Conversely, genes with low methylation levels were enriched in processes such as protein targeting and translation. These results indicate that transcripts encoding for transcriptional regulators are highly methylated in DCM hearts. Specifically, m<sup>6</sup>A-containing transcripts were enriched for genes involved in β catenin and calmodulin binding (Fig S1F). Highest methylation status of mRNAs involved in transcription has also been reported in human stem cells (Molinie et al, 2016). Fig 1F shows examples of m<sup>6</sup>A profiles of genes with varying m<sup>6</sup>A levels between non-failing and failing human myocardium. Overall, these data confirm the dynamic and regulatory character of m<sup>6</sup>A in the failing human myocardium.

m<sup>6</sup>A methylation machinery is present and functional in cardiomyocytes and affects cell growth

Next, the role of mRNA methylation in cardiomyocytes was investigated. Both, m<sup>6</sup>A writer Mettl3 and the eraser Fto are localized in the nucleus of isolated adult cardiomyocytes and neonatal myocytes (NRCM) as previously described for other cell types (Fig S2A) (Gulati et al, 2014; Schöller et al, 2018). We aimed to characterize the consequence of manipulating m<sup>6</sup>A levels in NRCM after siRNA knockdown of Mettl3 or Fto (Fig S2B). Mettl3 knockdown decreased m<sup>6</sup>A levels in myocytes, whereas knockdown of Fto increased overall m<sup>6</sup>A levels (Fig S2C). Consequences of altered m<sup>6</sup>A levels on cell size were analyzed. Hypertrophy of NRCM is blunted by Fto knockdown in response to α-adrenergic stimulation with phenylephrine (PE) treatment, whereas knockdown of Mettl3 increased the cell size (Fig S2D) in line with the augmented cell size, Mettl3 knockdown significantly increased the expression of hypertrophic markers Nppa and Nppb after PE treatment (Fig S2E).

Because our data suggest that lower m<sup>6</sup>A levels are associated with increased cell size, we tested whether increased m<sup>6</sup>A levels would block pathological growth in cardiac myocytes. Fto binds additional RNA species, including small nuclear RNA (snRNA) and tRNA (Wei et al, 2018), and recent reports showed that Fto also demethylates N6,2'-O-dimethyladenosine (m<sup>6</sup>Am) and snRNAs or tRNAs in addition to m<sup>6</sup>A (Mauer et al, 2017; Wei et al, 2018). Thus, we focused on studying Mettl3 in further experiments. Overexpression of the enzymatically active Mettl3 significantly increased m<sup>6</sup>A levels, whereas an enzymatically dead mutant of Mettl3 (Alarcón et al, 2015; Vu et al, 2017) did not increase m<sup>6</sup>A levels compared with the control group (Fig 2A). Correct nuclear localization of both active Mettl3 and inactive Mettl3 was confirmed by immunofluorescence (Fig S2F). Active Mettl3 blocked induction of cell size in response to PE (Fig 2B). In contrast, overexpression of enzymatically inactive Mettl3 mutant did not block cell growth, but slightly augmented cellular size compared with control cells only when treated with PE. Overall, these data show that manipulating m<sup>6</sup>A levels reciprocally regulate myocyte growth response in vitro.

Next, in vivo studies were performed targeting Mettl3 using cardiac-specific, AAV9-mediated Mettl3 overexpression to increase...
m^6A levels. Mettl3-overexpressing mice were subjected to transverse aortic constriction (TAC) surgery to induce pathological hypertrophy. Robust overexpression of Mettl3 and its nuclear localization in myocytes was confirmed (Fig S2G). Overexpression increased m^6A levels in mRNAs isolated from mice hearts (Fig S2H).

Heart size 2 wk after TAC was increased significantly in control mice (Fig 2C–F) and molecular markers of hypertrophy such as Nppa were significantly induced (Fig S2I). Pathological hypertrophic cellular growth was attenuated in hearts of Mettl3-overexpressing mice, as evidenced by the cross-sectional area of myocytes (Fig 2E and F). Myocytes in Mettl3-overexpressing hearts were significantly enlarged 2 wk post TAC surgery compared with sham-operated animals, but smaller than control TAC mice, without significant differences in hypertrophy marker expression between control TAC and Mettl3 TAC mice (Fig S2I). Consistent with blocked pathological growth, Mettl3 TAC-challenged hearts exhibited decreased fibrosis (Fig 2G and H) and decreased collagen transcription (Fig S2I) when compared with their control TAC-challenged counterparts.

Overall, these data suggest that m^6A methylation of mRNA directly impacts cardiomyocyte growth, and we provide evidence that mRNA modifications represent a hub for integrating signals which regulate the growth response in the myocardium. Manipulating m^6A levels in myocytes resulted in altered cellular growth response and cardiac remodeling both in vitro and in vivo. Importantly, phenotypic consequences are dependent on the enzymatic activity of Mettl3. Very recently, an elegant report analyzed the role of Mettl3 during hypertrophic cardiac growth by using cardiac-restricted gain- and loss-of-function mouse models (Dorn et al, 2018). This study showed-in contrast to our study—that increased Mettl3 expression caused (compensated) hypertrophy in vivo, whereas response to TAC was unchanged. Differences in the study design could explain some of the contrasting data. Dorn et al, 2018 used a transgenic model in the FVB background, where we used a C57Bl6/N background for the in vivo studies. Moreover, we used an AAV-based approach to overexpress Mettl3, which resulted in lower overexpression levels than a transgenic approach driven by the alpha myosin heavy chain (aMHC)-promoter in the study by Dorn et al, 2018. However, both studies point towards an important role of epitranscriptomic control on cell growth. More studies are clearly needed to fully understand this novel stress–response mechanism in the heart for maintaining normal cardiac function.

m^6A regulates RNA stability and translation efficiency in myocytes

Our loss-/gain-of-function experiments show that altered expression of Mettl3 regulates cell size both in vitro and in vivo. One possible mechanism could involve a regulatory role of m^6A in translational control of specific mRNAs, particularly under cellular stress conditions. Although mRNA translation is a complex and highly coordinated process, neither the importance nor the mechanisms of translational regulation in myocytes are studied to the same extent as for transcriptional control.
mRNA methylation in the myocardium

To understand the mechanism by which Mettl3 regulates cell size, we first defined the mRNA methylome early after TAC. Sequencing of m6A-specific immunoprecipitated mRNA was performed 2 d after surgery. This time point was chosen based on previous studies and defines a transition between early adaptation to compensated tissue remodeling with robust changes in gene expression and beginning of pathological growth (Volkers et al., 2013).

Surprisingly, the percentage of m6A in mRNA decreased substantially from 0.026% in sham-operated animals to 0.012% in response to a TAC surgery (Fig S3A). Also, fewer transcripts were enriched after sequencing of m6A-specific immunoprecipitated mRNAs compared with sham surgery (Fig S3B and Table S2). In total 1,567 genes were enriched after our IP protocol from sham-operated mice. This was associated with a decrease in Mettl3 expression 2 d post TAC surgery (Fig S3C). In line with our human data, transcripts from cardiac myocytes after TAC surgery were highly translated in response to TAC surgery (Fig 3D). We followed these differentially expressed transcripts in TAC-operated mice. This time point was chosen based on compensated tissue remodeling with robust changes in gene expression and beginning of pathological growth (Volkers et al., 2013). In line with our human data, transcripts from cardiac myocytes after TAC surgery were highly translated in response to TAC surgery (Fig S3C). In line with our human data, transcripts from cardiac myocytes after TAC surgery were highly translated in response to TAC surgery (Fig S3C).

Next, we analyzed the impact of mRNA methylation on translational efficiency in vivo. To investigate translational control in myocytes, we used the ribo-seq data (Fig 3A). Transcripts that were still methylated in TAC-operated mice were highly translated in response to TAC surgery (Fig 3A and B), whereas transcript levels measured by RNA-seq were unchanged (Figs 3B and S3E), suggesting that m6A affects translational efficiency during pathological growth. Again, highly translated methylated transcripts in TAC-operated mice were enriched for transcriptional regulation and cardiac muscular proteins, indicating a shift of the mRNA methylation towards transcripts of cardiac myocytes function and growth (Fig S3F).

Finally, we aimed to determine the Mettl3-dependent translational control in cardiac myocytes. Because ribo-seq methods still require a large number of cells, we used the murine HL-1 cardiomyocyte cell line as our source material. HL-1 cells can be used as a cardiomyocyte model as they have key characteristics of cardiac myocytes, although their metabolism and structure are less organized than primary cardiac myocytes (Claycomb et al., 1998; Eimre et al., 2008). Confluent and spontaneously beating murine HL-1 cells were infected with Mettl3 adenovirus to increase m6A levels (Fig S3G). We identified Mettl3-dependent, highly differentially translated mRNAs by ribo-seq (Figs 3C, S3H, and Table S3). Mettl3 targets were involved in regulation of cell cycle, DNA damage response, and again transcriptional regulation (Fig 3D). We followed these differentially expressed transcripts in our in vivo ribo-seq data from TAC-operated mice. Transcripts that are highly translated in Mettl3-overexpressing cardiac myocytes were highly translated in response to TAC surgery and vice versa (Fig 3E). In contrast, transcript levels of these
methylated transcripts genes were again unchanged in response to TAC, indicating that mRNA methylation by Mettl3 affects translational efficiency of specific transcripts during pathological growth in cardiac myocytes.

We validated Mettl3-dependent translation of two candidates (Arhgef3 and Myl2) by qRT-PCR on polysomal fractions from control or Mettl3-overexpressing cardiomyocytes. Overall translation was unchanged in Mettl3-overexpressing myocytes as assessed by polysome profiles (Fig 4A). However, Arhgef3 was significantly less, whereas Myl2 translated more in our HL-1 Ribo-seq data. In contrast, mRNA levels remain unchanged after Mettl3 overexpression (Fig 4B). As predicted by our Ribo-seq data, Arhgef3 transcript levels were decreased in polysomal fractions, whereas Myl2 levels increased after Mettl3 overexpression (Fig 4C). Increased Mettl3 dependent methylation of Arhgef3 and Myl2 transcripts were also validated by qRT-PCR after m6A-precipitated mRNA from Mettl3- or control-HL-1 cells compared with the input mRNA (Fig 4D). Previous studies suggested that methylation of transcripts affects mRNA stability and decay (Wang et al, 2015). In line, mRNA half-life measurement by blocking transcription with actinomycin D in NRCM showed that Mettl3 decreased the mRNA stability of the translationally down-regulated Arhgef3 or Polr3d (Fig 4E), whereas stability of Myl2 mRNAs was increased by Mettl3. Finally, Mettl3 overexpression caused decreased Arhgef3 protein levels, whereas Myl2 levels were increased in Mettl3-overexpressing myocytes (Fig 4F and G). In contrast to our in vitro data, mice overexpressing Mettl3 in the heart showed decreased Myl2 expression both during sham and TAC conditions (Fig 4H and I), whereas Arhgef3 expression increased both during TAC conditions in Mettl3-overexpressing mice and in control animals. Intriguingly, m6A enrichment of Arhgef3 and Myl2 changed at different time points after TAC compared with sham-operated animals (Fig S3I). We speculate that longer Mettl3 overexpression results in different methylation patterns in vivo compared with our in vitro data. Moreover, different expression levels of m6A reader proteins could certainly affect translation of methylated transcripts after long-term overexpression of Mettl3. Ultimately, more studies are needed to fully understand how m6A methylation regulates translation in myocytes.

In summary, our data suggest that m6A regulates and affects cardiomyocyte fate by adding a posttranscriptional regulation step to gene expression by influencing mRNA stability and translation efficiency. Using Ribo-seq, we identified subsets of mRNAs, which
are translationally dependent on methylation status or Mettl3 activity. Our findings support the paradigm that mRNA modifications in the heart play important roles in the heart by 1) validating the expression of Mettl3 and Fto in the myocardium, 2) demonstrating dynamic mRNA methylome in HF both in human and murine hearts, 3) showing effects upon cell growth in vitro and in
growth control and which specify targets are responsible for the phenotypic consequences are unknown. Overall methylation early after pathological stress in murine hearts is decreased, whereas human HF samples showed increased m^6^A levels. Whether this is due to altered Mettl3 or Fto activity needs to be investigated. Also, it is unknown how enzymatic activity of writers and erasers is regulated. Similarly, how increased m^6^A levels are explained in a complex interplay of writers and erasers in failing myocardium remains unclear. Recently, a beneficial role of the demethylase Fto in cardiac function after myocardial infarction has been reported (Mathiyalagan et al, 2018). This study identified that Fto selectively demethylates cardiac contractile transcripts such as Serca2a or RyR2 and thereby increases calcium handling and cardiac contractility. Our study did not identify a specific effect of Mettl3 on the translational status of Serca2a or RyR2. Whether writers or erasers compete with targets under different stress conditions and how this might be regulated is unknown and requires further studies. Our data suggest that the enzymatic activity of Mettl3 positively and negatively regulates translational status of specific transcripts. This clearly could be the result of regulation of mRNA stability, degradation, or direct rate of translation. In fact, m^6^A has been shown to have both stimulatory (Meyer et al, 2015; Wang et al, 2015) and inhibitory effects (Choi et al, 2016; Slobodin et al, 2017) on translation. We speculate that Mettl3 affects translational efficiency by methylating mRNAs encoding for proteins involved in transcriptional regulation which could fine-tune the response to cellular stress. Alternatively, because m^6^A reader such as Ythdf1-3 (Wang et al, 2015; Shi et al, 2018, 2017) can regulate translational efficiency of methylated transcripts, especially in cellular stress conditions, changes in expression or activity of those readers might alter translational efficiency of methylated transcripts. We validated Mettl3-dependent gene expression regulation of two interesting candidates in follow-up experiments. Mettl3 decreases Arhgef3 protein levels in vitro. Arhgef3 (also known as Xpln) is a Rho guanine nucleotide exchange factor and has been found to interact with the protein kinase mechanistic target of rapamycin (mTOR) (Khanna et al, 2013). Increased levels of Arhgef3 have been shown to stimulate mTORC1. Moreover, increased activity of mTORC1 has been shown to contribute to cardiac hypertrophy and HF (Volkers et al, 2013; Sciarretta et al, 2018), and ongoing studies will investigate the role of Arhgef3 on mTORC1 regulation during pathological growth. Myosin light chain-2 (Myl2) expression increased after Mettl3 overexpression in vitro, and its expression is slightly increased after TAC surgery. Myl2 is a sarcomeric protein that belongs to the EF-hand calcium-binding protein superfamily. Genetic loss-of-function studies in mice demonstrated the essential role for Myl2 in cardiac contractile function (Sheik et al, 2015), but it is unknown if increased expression of Myl2 is needed in addition to the characterized regulation by phosphorylation for the adaptation to increased workload in response to acute pressure overload. Additional studies will be needed to fully understand whether m^6^A-dependent gene expression control of Arhgef3 and Myl2 levels causally contributes to inhibition of pathological growth after Mettl3 overexpression.

Thus, mRNA modifications represent an additional way of controlling gene expression in the myocardium. Once specific targets will be elucidated, manipulations of m^6^A levels could be a powerful approach to prevent worsening of cardiac function. It may become possible to alter mRNA modifications therapeutically by engineering RNA-modifying enzymes with altered substrate specificity or to test whether novel small molecules that affect the formation of mRNA modifications have therapeutic values. Those approaches will open exciting prospects of developing new therapies for diseases caused by m^6^A dysregulations, including heart diseases.

Materials and Methods

Animal tissues

All experiments were performed in 10-wk-old male mice unless otherwise indicated. The RiboTag mice were purchased from the Jackson Laboratory (JAX ID 011029). The mice were housed in a temperature- and humidity-controlled facility with a 12-h light–dark cycle. The RiboTag mouse was bred to the α-MHC-Cre mice to obtain Rpl22^cre−^expressing homozygous mice in cardiac myocytes. At 10 wk of age, male mice underwent TAC (27 gauge needle) or sham operation, as previously described (Rockman et al, 1991) (Doroudgar et al, 2015). For echocardiography, the mice were anesthetized with 2% isoflurane and scanned using a Vevo2100 imaging system (Visual Sonics) as previously described (Volkers et al, 2014). Institutional Animal Care and Use Committee approval was obtained for all animal studies.

Human tissue

The characterization of samples and patient data has been approved by the ethics committee, and medical faculty of Heidelberg and participants have given written informed consent. Biopsy specimens were obtained from the apical part of the free left ventricular wall (LV) from DCM, or control LV biopsy specimens were obtained from stable and symptom-free patients after heart transplantation. Biopsies were rinsed with NaCl (0.9%) and immediately transferred and stored in liquid nitrogen until DNA or RNA was extracted. Total RNA was extracted from biopsies using the RNeasy kit according to the manufacturer’s protocol (QIAGEN). For m^6^A-seq analysis, RNA has been isolated from explanted human hearts from patients suffering chronic HF. Control RNA from non-failing LV tissue has been obtained commercially (Biocat) or from donor hearts that could not be used for transplantations.

Preparation of tissue lysates

For heart homogenates, male αMHC-Cre-RiboTag mice were euthanized, and their hearts were quickly excised, washed in PBS containing 100 μg/ml cycloheximide (CHX), and snap-frozen in liquid nitrogen as previously described (Siede et al, 2017). LV tissue was homogenized using a tissue homogenizer (Bullet Blender, Next
Advance) in five volumes of ice-cold polysome buffer (20 mM Tris, pH 7.4, 10 mM MgCl2, 200 mM KCl, 2 mM DTT, 100 μg/ml CHX, 1% Triton X-100, and 1 U DNase/μl) containing 100 μg/ml CHX. Homogenates were centrifuged at 4°C and 15,000 g for 10 min, and the supernatant was immediately used in the further steps. 100 μl of lysate was used as input, from which RNA was extracted using Trizol. The remaining lysate was used for cell type specificity analysis of translated RNAs. This was achieved by anti-HA IP of polysomes. Anti-HA magnetic beads (88836; Thermo Fisher Scientific; 100 μl per heart) were washed with 1,000 μl polysome lysis buffer three times. The lysate was then added to anti-HA magnetic beads and incubated with rotation at 4°C overnight. The beads were then washed three times with 500 μl of high salt buffer (20 mM, Tris pH 7.4, 10 mM MgCl2, 300 mM KCl, 2 mM DTT, and 1% Triton X-100). The washed beads were subjected to RNA extraction for library construction and subsequent high-throughput sequencing using the Illumina TruSeq Ribo Profile kit or immunoblotting analysis.

**Polysome profiling**

Sucrose solutions were prepared in polysome gradient buffer and 20 U/ml SUPERase-In (Ambion). Sucrose density gradients (10–50% wt/vol) were freshly made in SW40 ultracentrifuge tube using a BioComp Gradient Master (BioComp) according to the manufacturer's instructions. Tissue lysates were loaded onto sucrose gradients, followed by centrifugation for 250 min at 220,000 g, 4°C, in an SW40 rotor. Separated samples were fractionated on 0.375 ml/min by using a fractionation system BioComp Gradient Station (BioComp) that continually monitors OD254 values. The fractions were collected into tubes at 0.3-mm intervals. Isolation of RNA from fractions was performed by QIAzol (QIAGEN) and Quick RNA Mini-prep kit (Zymo Research) followed by cDNA synthesis of 200 ng RNA using the iScript cDNA Synthesis kit (Bio-Rad). Before extraction, 20 μg of Renilla luciferase in vitro–transcribed mRNA were added to the fractions as an internal standard. qPCRs were run with 1:10 dilutions of the cDNA samples. Data were normalized to the luciferase and the sample input signal.

**m6A immunoprecipitation and sequencing**

Human and mouse heart tissue were lysed in 700 μl lysis buffer (20 mM Tris, pH 7.4, 10 mM MgCl2, 200 mM KCl, 2 mM DTT, 100 μg/ml CHX, 1% Triton X-100, and 1U DNase/μl) using a tissue homogenizer (Bullet Blender, Next Advance). The tissue was homogenized further by passing the lysate through a 23-gauge syringe needle 10 times. Homogenates were centrifuged at 4°C and 18,000 g for 10 min, and the supernatant was immediately used in the further steps. For complete lysis, the samples were kept on ice for 10 min and subsequently centrifuged at 20,000 g to precipitate cell debris.

Ribosomal RNA was depleted from total RNA samples by ribo zero (MRZ311124; Illumina). 50 μg of total RNA was used. Non-IP RNA was stored for RNA-seq analysis.

Ribosomal depleted RNA was subjected to m6A IP. mRNAs were immunoprecipitated by m6A antibody (ab151230; Abcam)–coupled protein A/G magnetic beads (88802; Pierce). Elution was performed in all cases with m6A salt. Libraries were constructed using Illumina TruSeq protocols and sequenced by the Cologne Center as 75-bp single reads. All sequencing data were subjected to the same preprocessing steps: reads are trimmed (adapter removal) and quality clipped with FlexBar (Dodd et al, 2012). All remaining reads (>18 bp in length) are mapped either against the murine 45S rRNA precursor sequence (BK000964.3) or the human 45S rRNA precursor sequence (NR_046235.1) with Bowtie 2 to remove RNA contaminant reads. We used the splice-aware STAR read aligner (Dobin et al, 2013) (release 2.5.1b) to map reads from input RNA and m6A IP libraries against the respective EnsEMBL genome assemblies (release 87). Differential enrichment analyses on IP/input gene read counts was conducted using the edgeR package (McCarthy et al, 2012) for each condition separately. We used a two-factor design (IP or input, sample number) and assessed the significance of the IP/input contrast. The adjusted P-values were reported for every expressed gene locus (>10 counts over all input samples). Enrichment was calculated as log2-fold change (logFC) of ratio of reads from immunoprecipitated mRNA sequencing and mRNA sequencing and defined as enriched if logFC > 0 and FDR < 0.05 and as not enriched/m6A low if logFC < -1 and FDR < 0.05.

**Parallel generation of ribosome profiling and RNA libraries**

To accurately dissect translation and transcription, both Ribo-seq and RNA-seq libraries were prepared for each biological replicate from aMHC-Cre-positive RiboTag mice after sham or TAC surgeries. Cardiomyocyte-specific ribosomes were isolated like previously described (Siede et al, 2017). Briefly, the tissue was homogenized in polysome buffer, and lysate was used as the input for RNA-seq.

The remaining lysate was used for direct IP of polysomes. Anti-HA magnetic beads (88836; Thermo Fisher Scientific; 100 μl per heart) were washed with 1,000 μl polysome lysis buffer three times. The lysate was then added to HA magnetic beads and incubated with rotation at 4°C overnight. The beads were then washed three times with 500 μl of high salt buffer (20 mM, Tris pH 7.4, 10 mM MgCl2, 300 mM KCl, 2 mM DTT, and 1% Triton X). The washed beads were subjected to RNA extraction for Ribo-seq library construction. Libraries were generated according the the mammalian ARTseq kit (Illumina). Barcodes were used to perform multiplex sequencing and create sequencing pools containing at least eight different samples and always an equal amount of both RNA and RPF libraries. Sample pools were sequenced on the NextSeq platform using 75-SE sequencing chemistry.

**Sequencing data processing and quality control**

Ensembl annotations were used for the analysis. For each gene, all its annotated coding sequence (CDS) regions were extracted and then concatenate into a single metagene. A previously published pipeline was used for quality control and data processing (Malone et al, 2017). A fully Bayesian translation prediction approach was used—RP-BP. Standard techniques were used to construct the profiles. Adapters and low-quality reads were removed. Reads mapping to ribosomal and mRNA sequences were removed. Reads to the genome were aligned with a splice-aware aligner and reads removed with multiple genomic alignments. The Ribo-seq profiles are constructed using the same steps; however, the BPPS method was used to shift aligned reads to properly account for the P-site of
Generation of the mutant Mettl3 (Mettl3 Mut) construct

Two point mutations were introduced within the catalytic site of Mettl3 (Vu et al., 2017) in two mutagenesis steps by using the following PCR protocol with pAd_Mettl3 as a parent plasmid and specifically designed primers containing the desired mutations using the Agilent QuickChange II Site-Directed Mutagenesis kit as per the manufacture’s instruction. The obtained plasmid was transformed into NEB α-5 E. coli following the High Efficiency Transformation Protocol from New England Biolabs. Validation of the created plasmid was performed by sequencing, and the mutant construct was cloned into a pAd vector using the LR recombination protocol by Thermo Fisher Scientific.

Immunocytofluorescence of mouse heart sections

Hearts were cleared by retroperfusion in situ with PBS at 70 mmHg, arrested in diastole with 60 mM KCl, fixed by perfusion for 15 min with 10% formalin (HT501128; Sigma-Aldrich), excised, fixed in formalin for 24 h at room temperature, and embedded in paraffin. Paraffin-embedded hearts were sectioned and placed on slides, which were then deparaffinized and then rehydrated. Antigen retrieval was achieved by boiling the slides in 10 mM citrate (pH 6.0) for 12 min, after which the slides were washed several times with distilled water, and once with Tris/NaCl, or TN buffer (100 mM Tris and 150 mM NaCl). Primary antibodies were diluted in TNB and added to slides which were incubated at 4°C for ~12–16 h. The samples were then washed with TN buffer and incubated with secondary antibodies at room temperature in the dark for 2 h. Images were obtained using a Zeiss Observer.Z1 fluorescence microscope. Images were obtained with a 20× objective.

Immunoblotting

Samples were combined with the appropriately concentrated form of Laemmli sample buffer and then boiled before SDS–PAGE followed by transfer to polyvinylidene difluoride (PVDF) membranes.

Quantitative real-time PCR

Total RNA was isolated from frozen heart or cultured cells by using Quick-RNA MiniPrep (Zymo Research) and reverse-transcribed into cDNA by using iScript Reverse Transcription Supermix (Bio-Rad). Quantitative real-time PCR was performed on all samples in triplicate using iTAQ SYBR Green PCR kit (Bio-Rad) according to the manufacturer’s instructions. Information about the primers used in the study is shown in Table S5.

m^6^-A ELISA

To detect overall levels of m^6^-A displaying RNAs, the m^6^-A ELISA (ab185912; Abcam) was performed per the protocol. Total RNA was isolated from the cultured cell lysates by using the Quick-RNA MiniPrep kit form Zymo Research including an on-gDNA removal step and an additional in-column DNase I digest step. mRNA was isolated by polyA enrichment using oligo(dt) magnetic beads (NEB) according to the manufacturer’s instructions.

m^6^-A dot blotting

mRNA was denatured at 75°C for 5 min, spotted, and cross-linked to a positively charged nylon membrane 2+ in UV-Stratalinker with 1,800 μJ/cm^2 at 254 nm. The membrane was probed with m^6^-A antibody (ab151230, 1:1,000; Abcam).

GO analysis

GO term enrichment analysis was performed using the subset of expressed protein-coding genes as background set (DAVID). Categories with a P-value <0.05 were retained, and a subset was visualized with R.
Data availability

The datasets produced in this study are available in the following databases: M^A-seq, RNA, and Ribo-seq data have been uploaded to SRA with the following ID: SRP156230.

Statistics

Cell culture experiments were performed at least two to four times with n = at least two biological replicates (cultures) for each treatment. In vivo experiments were performed on at least three biological replicates (mice) for each treatment. The investigators have been blinded to the sample group allocation during the experiment and analysis of the experimental outcome. Unless otherwise stated, values shown are mean ± SEM and statistical treatments are one-way ANOVA followed by Bonferroni’s post hoc comparisons.

Supplementary Information

Supplementary Information is available at https://doi.org/10.26508/lsa.201800233.

Acknowledgements

A Gorska, P Most, HA Katus, and C Dieterich acknowledge the DZHK (German Centre for Cardiovascular Research) Partner Site Heidelberg/Mannheim. C Dieterich acknowledges funding from the Klaus-Tschira Stiftung GmbH. M Völkers is supported by Deutsche Forschungsgemeinschaft (DFG VO 1659 2/1 and DFG VO 1659 4/1), and Baden Württemberg Stiftung and E Malovrh by Heidelberg Biosciences International Graduate School.

Author Contributions

V Kmiećczyk: data curation, formal analysis, investigation, methodology, and writing—original draft, review, and editing.

E Riecher: data curation, formal analysis, investigation, methodology, and writing—original draft, review, and editing.

L Kalinski: formal analysis, investigation, and methodology.

E Boileau: resources and formal analysis.

E Malovrh: formal analysis, investigation, and methodology.

B Malone: software and methodology.

A Gorska: supervision, investigation, methodology, and writing—review and editing.

C Dieterich: conceptualization, resources, software, formal analysis, supervision, methodology, and writing—review and editing.

M Völkers: conceptualization, resources, formal analysis, supervision, funding acquisition, investigation, visualization, methodology, and writing—original draft, project administration, review, and editing.

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

References

Alarcón CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF (2015) N^6-methyladenosine marks primary microRNAs for processing. Nature 519: 482–485. doi:10.1038/nature14281

Boissel S, Reish O, Proulx K, Kawagoe-Takaki H, Sedgwick B, Yeo GSH, Meyre D, Golzio C, Molinari F, Kadhom N, et al (2009) Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. Am J Hum Genet 85: 106–111. doi:10.1016/j.ajhg.2009.06.002

Bui AL, Horwich TB, Fonarow GC (2011) 2006 National Hospital Discharge Survey. Nat Rev Cardiol 8: 1–20. doi:10.1038/nrcardio.2010.165

Choi J, Leong KW, Demirci H, Chen J, Petrov A, Prabhakar A, O’Leary SE, Dominissini D, Rechavi G, Soltis SM, et al (2016) N^6-methyladenosine in mRNA disrupts tRNA selection and translation-elongation dynamics. Nat Struct Mol Biol 23: 110–115. doi:10.1038/nsmb.3148

Claycomb WC, Lanson NA, Stallworth BS, Ieong KW, Delcarpio JB, Bahinski A, Izzo NJ (1998) HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 95: 2979–2984. doi:10.1073/pnas.95.6.2979

Dobin A, Davis CA, Schlesinger F, Flicek P,记性 闰, Wu Y, Pertea M, et al (2013) STAR: Ultrafast universal RNA-seq aligner [supplementary data]. Bioinformatics 29: 15–21. doi:10.1093/bioinformatics/bts635. Available at: https://academic.oup.com/bioinformatics/article/29/1/15/272537

Dodd M, Roehr J, Ahmed R, Dieterich C (2012) FLEXBAR—flexible barcode and adapter processing for next-generation sequencing platforms. Biology (Basel) 1: 895–905. 10.3390/biology1030895. Available at: https://www.mdpi.com/2079-7737/1/3/895

Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Dixon M, Ungar L, Olsenberg S, Cesarkas K, Jacob-Hirsch J, Amargiño N, Kupiec M, et al (2012) Topology of the human and mouse m^6^A RNA methylomes revealed by m^6^A-seq. Nature 485: 201–206. doi:10.1038/nature11112

Dorn LE, Lasman L, Chen J, Xu X, van Berlo JH, Accornero F (2018) The m 6 A mRNA methylase METTL3 controls cardiac homeostasis and hypertrophy. Circulation 139: 533–545. doi:10.1161/CIRCULATIONAHA.118.036146

Doroudgar S, Völkers M, Thurairov OJ, Khan M, Mohsin S, Respress JL, Wang W, Gude N, Mühl O, Wehrens XHT, et al (2015) Hrd1 and ER-associated protein degradation, ERAD, are critical elements of the adaptive ER stress response in cardiac myocytes. Circ Res 117: 536–546. doi:10.1161/circresaha.115.306993

Eimre M, Paju K, Pelloux S, Beraud N, Kadaja L, Gruno M, Peet N, Orlova E, Remmelkroon R, et al (2008) Distinct organization of energy metabolism in HL-1 cardiac cell line and cardiomyocytes. Biochim Biophys Acta 1777: 514–524. doi:10.1016/j.bbabio.2008.03.019. Available at: https://www.sciencedirect.com/science/article/pii/S0005272808000625. Accessed February 1, 2019.
Malone (2014) Gene expression regulation mediated through reversible m^6^A RNA methylation. Nat Rev Genet 15: 293–306. doi:10.1038/nrg3724

Geula S, Moshtchik-Moshkovitz S, Dominissini D, Mansour AAF, Kol N, Salmon-Dixon M, Hershkovitz V, Peer E, Mor N, Manor YS, et al (2015) m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. Science 347: 1002–1006. doi:10.1126/science.1264147

Gilbert WV, Bell TA, Schaening C (2016) Messenger RNA modifications: Form, distribution, and function. Science 352: 1408–1412. doi:10.1126/science.aad8771

Gulati P, Avezov E, Ma M, Antrobus R, Lehner P, Lai A, Nietsch M, Avezov E, Ma M, Antrobus R, Lehner P, O’Hara S, et al (2016) A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514: 102–106. doi:10.1038/nature13596

He C (2010) Grand challenge commentary: RNA epigenetics? Nat Chem Biol 6: 863–865. doi:10.1038/nchembio.682. Available at: http://www.nature.com/doi/full/10.1038/nchembio.682. Accessed January 31, 2019.

Ingolia NT (2016) Ribosome footprint profiling of translation throughout the genome. Cell 165: 22–33. doi:10.1016/j.cell.2016.02.066

Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Li C, Lindahl T, Pan T, Yang YG, et al (2014) A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514: 102–106. doi:10.1038/nature13596

Khanna N, Fang Y, Yoon MS, Chen J (2013) XPLN is an endogenous inhibitor of cell. Circ Res 112: 33794. doi:10.1161/CIRCULATIONAHA.118.033794

Zhang S, Kohlbrenner E, Chepurko E, et al (2018) FTO-dependent m^6^A methylation mediates through reversible m^6^A RNA methylation. Nat Chem Biol 14: 313–326. doi:10.1038/nchembio.20140111

Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Li C, Lindahl T, Pan T, Yang YG, et al (2014) A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514: 102–106. doi:10.1038/nature13596

He C (2010) Grand challenge commentary: RNA epigenetics? Nat Chem Biol 6: 863–865. doi:10.1038/nchembio.682. Available at: http://www.nature.com/doi/full/10.1038/nchembio.682. Accessed January 31, 2019.

Khanna N, Fang Y, Yoon MS, Chen J (2013) XPLN is an endogenous inhibitor of mTORC2. Proc Natl Acad Sci U S A 110: 15979–15984. doi:10.1073/pnas.130434110

Koibataishi N, Kass DA (2012) Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat Rev Cardiol 9: 147–157. doi:10.1038/nrcardio.2011.172

Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X, et al (2014) A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol 10: 93–95. doi:10.1038/nchembio.1432. Available at: http://www.nature.com/articles/nchembio.1432. Accessed February 5, 2019.

Malone B, Atanassov I, Aeschimann F, Li X, Großhans H, Dieterich C (2017) Reversible methylation of m^6^A RNA in the cytoplasm. Nat Rev Genet 18: 1563. doi:10.1038/nrg.200421454

Schöller E, Weichmann F, Treiber T, Ringle S, Treiber N, Flatley A, Feederle R, Bruckmann A, Meister G (2018) Interactions, localization, and phosphorylation of the m^6^A generating METTL3–METTL14–WTAP complex. RNA 24: 499–512. doi:10.1071/RN16063.117

Sciarretta S, Forte M, Fritag G, Sadoshima J (2018) New insights into the role of mitor signaling in the cardiovascular system. Circ Res 122: 489–505. doi:10.1161/circresaha.117.311147

Sheikh F, Lyon RC, Chen J (2015) Functions of myosin light chain-2 (MYL2) in cardiac muscle and disease. Gene 569: 14–20. doi:10.1016/j.gene.2015.06.027. Available at: https://www.sciencedirect.com/science/article/pii/S0378111915007350?via%3Dihub. Accessed February 4, 2019.

Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C, He C (2017) YTHDF3 facilitates translation and decay of N^6^-methyladenosine-modified RNA. Cell Res 27: 315–328. doi:10.1038/cr.2017.15

Shi H, Zhang X, Weng YL, Lu Z, Liu Y, Lu Z, Li J, Hao P, Zhang Y, Zhang F, et al (2018) m^6^A facilitates hippocampus-dependent learning and memory through YTHDF1. Nature 563: 249–253. doi:10.1038/nature24586.1016661

Siede D, Rapti K, Gorska AA, Katus HA, Altmüller J, Boeckel JN, Meder B, Maack B, Atanassov I, Aeschimann F, Li X, Großhans H, Dieterich C (2017) Transcription impacts the efficiency of mRNA translation via co-transcriptional N6-adenosine methylation. Cell 169: 326–337.e12. doi:10.1016/j.cell.2017.03.031

Tan FL, Moravec CS, Li J, Apperson-Hansen C, McCarthy PM, Young JB, Bond M (2002) The gene expression fingerprint of human heart failure. Proc Natl Acad Sci USA 99: 11387–11392. doi:10.1073/pnas.16270099
Völkers M, Doroudgar S, Nguyen N, Konstandin MH, Quijada P, Din S, Ornelas L, Thuerauf DJ, Gude N, Friedrich K, et al (2014) PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity. *EMBO Mol Med* 6: 57–65. doi:10.1002/emmm.201303183

Völkers M, Konstandin MH, Doroudgar S, Toko H, Quijada P, Din S, Joyo A, Ornelas L, Samse K, Thuerauf DJ, et al (2013) Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage. *Circulation* 128: 2132–2144. doi:10.1161/circulationaha.113.003638

Volkers M, Toko H, Doroudgar S, Din S, Quijada P, Joyo AY, Ornelas L, Joyo E, Thuerauf DJ, Konstandin MH, et al (2013) Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1. *Proc Natl Acad Sci USA* 110: 12661–12666. doi:10.1073/pnas.1301455110

Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, Chou T, Chow A, Saletore Y, Mackay M, et al (2017) The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. *Nat Med* 23: 1369–1376. doi:10.1038/nm.4416

Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H, He C (2015) N6-methyladenosine modulates messenger RNA translation efficiency. *Cell* 161: 1388–1399. doi:10.1016/j.cell.2015.05.014. Available at: https://www.sciencedirect.com/science/article/pii/S0092867415005620?via%3Dihub. Accessed February 4, 2019.

Wei J, Liu F, Lu Z, Fei Q, Ai Y, He PC, Shi H, Cui X, Su R, Klungland A, et al (2018) Differential m6A, m3A, and m7A demethylation mediated by FTO in the cell nucleus and cytoplasm. *Mol Cell* 71: 973–985.e5. doi:10.1016/j.molcel.2018.08.011

License: This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).